UPDATE: Goldman Sachs Reiterates Buy on Johnson & Johnson, Reduces PT to $74

Goldman Sachs reiterated its Buy rating on Johnson & Johnson JNJ. At the same time, the rating agency reduced its price target on the company's stock from $76 to $74. On Monday, JNJ closed the day at $61.12. Its shares added 0.7% to their value in today's pre-market trading to stand around $61.55.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Price TargetReiterationAnalyst RatingsGoldman SachsHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!